+1 Recommend
1 collections
      • Record: found
      • Abstract: found
      • Article: found

      Autoantibodies to Cardiolipin and Beta-2-Glycoprotein-I in Coronary Artery Disease Patients with and without Hypertension

      Read this article at

          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.


          Background: Autoantibodies to cardiolipin (aCL) and β<sub>2</sub>-glycoprotein-I (β2GPI) are considered proatherogenic. Elevated levels of both antibodies have been reported in hypertension. Nonetheless, there are no data regarding an association between these autoantibodies and hypertension in coronary artery disease. Methods: The levels of aCL and anti-β2GPI antibodies were measured in patients having coronary artery disease with (n = 82) or without (n = 36) hypertension, in association with other major risk factors for coronary artery disease. Results: The levels of aCL and anti-β2GPI antibodies were (OD at 405 nm) 0.23 ± 0.14 and 0.22 ± 0.12 in the normal blood pressure group, as opposed to 0.24 ± 0.12 and 0.20 ± 0.12 in the hypertensive group, respectively (p = 0.67; 0.42). No significant difference in either antibody levels was found between hypertensive patients with normal and abnormal blood pressure measurements. The presence of additional risk factors did not affect antibody levels in normotensive patients. However, in the hypertensive group, the presence of smoking was associated with significantly decreased anti-β2GPI antibody levels, whereas no change was found in aCL. Further, patients who had hypertension, smoking and hypercholesterolemia, had significantly decreased anti-β2GPI antibody levels compared with patients without any of these risk factors (0.13 ± 0.04 versus 0.23 ± 0.13, respectively; p = 0.02). Conclusion: Hypertension is not associated with modification of aCL and anti-β2GPI antibody levels in coronary artery disease patients. However, there are elevated anti-β2GPI antibody levels in patients without conventional risk factors compared with patients with these risk factors.

          Related collections

          Most cited references 2

          • Record: found
          • Abstract: found
          • Article: found

          Antibodies to Beta 2 -Glycoprotein I in Ischemic Stroke

          Antibodies to β 2 -glycoprotein (β 2 -GPI) have been associated with recurrent thrombotic events in patients with systemic lupus erythematosus. The present study investigated the prevalence of antibodies to β 2 -GPI in an unselected group of patients with ischemic stroke. One hundred and twenty-one sera from patients with ischemic stroke and 174 control sera from patients with nonischemic neurological disorders (n = 43) and healthy subjects (n = 131) were tested for antibodies to β 2 -GPI by a solid-phase ELISA. Twenty-nine stroke patients (24%) had antibodies to β 2 -GPI. Of the 43 patients in the neurological control group, 2 were positive. For comparison between the groups, Fisher’s exact test was used for categorical variables and ANOVA for antibody titers. Antibody levels and frequencies of positivity were significantly different between the study groups. None of the sera from the healthy control group had abnormal antibody levels. When risk factors and associated diseases were taken into account, a marginal association was found between the presence of antibodies to β 2 -GPI and hypertension (p = 0.036). This study demonstrates a significant prevalence of antibodies to β 2 -GPI in an unselected stroke population.
            • Record: found
            • Abstract: not found
            • Article: not found

            Autoantibodies to oxidized low-density lipoprotein in coronary artery disease

             Y SHERER (2001)

              Author and article information

              S. Karger AG
              March 2002
              07 March 2002
              : 97
              : 1
              : 2-5
              aDepartment of Medicine B and Center of Autoimmune Diseases, bCardiac Rehabilitation Institute, Sheba Medical Center, Tel-Hashomer, and Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel
              47411 Cardiology 2002;97:2–5
              © 2002 S. Karger AG, Basel

              Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

              Page count
              Tables: 2, References: 14, Pages: 4
              General Cardiology


              Comment on this article